Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.
暂无分享,去创建一个
M. O’Kennedy | A. Truyts | C. Abolnik | Y. Lemmer | T. Hermanus | R. Chapman | S. Gers | K. Goosen | Kamogelo M Sepotokele | Martin Magwaza | Osborn Mahanjana | P. Moore | Tanja Smith | Georgia Schäfer | Ilse du Preez | T. Suliman | W. Preiser | M. Shaw | Robyn Roth | John Chipangura
[1] M. Shaw,et al. A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters , 2023, Frontiers in Plant Science.
[2] M. O’Kennedy,et al. Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits , 2023, Vaccine.
[3] W. Phoolcharoen,et al. Chapter 12 SARS-CoV-2 vaccines: current trends and prospects of developing plant-derived vaccines , 2022, Biomedical Innovations to Combat COVID-19.
[4] X. Fang,et al. A potent, broadly protective vaccine against SARS-CoV-2 variants of concern , 2022, npj Vaccines.
[5] D. Vinh,et al. Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19 , 2022, Nature Communications.
[6] Jie Zhou,et al. Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines , 2022, Journal of medical virology.
[7] J. Izopet,et al. Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection , 2022, Vaccines.
[8] A. West,et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models , 2022, Science.
[9] N. Heaton,et al. The Impact of Estrogens and Their Receptors on Immunity and Inflammation during Infection , 2022, Cancers.
[10] I. Mysorekar,et al. Golden Syrian Hamsters as a Model for Revisiting the Role of Biological Sex Differences in SARS-CoV-2 Infection , 2021, mBio.
[11] S. Madhi,et al. Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. , 2021, Vaccine.
[12] Priya S. Shah,et al. Contributions of the international plant science community to the fight against human infectious diseases – part 1: epidemic and pandemic diseases , 2021, Plant biotechnology journal.
[13] Marc‐André D'Aoust,et al. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19 , 2021, Nature Medicine.
[14] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[15] M. Giordano,et al. Immune system and COVID-19 by sex differences and age , 2021, Women's health.
[16] T. Vesikari,et al. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials , 2020, The Lancet.
[17] Martin F. Bachmann,et al. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.
[18] G. Lomonossoff,et al. pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. , 2009, Plant biotechnology journal.
[19] R. Roden,et al. Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines , 2009, Journal of Virology.
[20] A. Krieg,et al. Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.